IPO · STOK
Stoke Therapeutics, Inc.
Formerly ASOthera Pharmaceuticals, Inc.
Stoke Therapeutics, Inc. (STOK) priced its initial public offering on Jun 19, 2019 at $18.00 per share, above its $14.00–$16.00 range, raising $142M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $566.3M. J.P. Morgan was lead-left underwriter, joined by TD Cowen, Credit Suisse and Canaccord Genuity. Davis Polk advised the underwriters.
- Status
- IPO
- Ticker
- STOK
- Exchange
- Nasdaq Global Select
- Priced
- Jun 19, 2019
- IPO price
- $18.00
- Price range
- $14.00–$16.00
- Raised
- $142M
- Market cap at IPO price
- $566.3M
- First filed
- May 23, 2019
- Underwriters
- J.P. Morgan, TD Cowen, Credit Suisse and Canaccord Genuity
- Underwriters' counsel
- Davis Polk
- Sector
- Biotech & pharma
- Country / state
- MA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed May 23, 2019
- Latest amendment Jun 12, 2019
- Final prospectus (424B4) Jun 19, 2019
- All filings on EDGAR CIK 1623526
Other Biotech & pharma IPOs in 2019
- BridgeBio Pharma, Inc.BBIO · Jun 28, 2019 · $348.5M
- Adaptive Biotechnologies CorpADPT · Jun 27, 2019 · $300M
- Morphic Holding, Inc.MORF · Jun 27, 2019 · $90M
- Akero Therapeutics, Inc.AKRO · Jun 20, 2019 · $92M
- Atreca, Inc.BCEL · Jun 20, 2019 · $125M
- Prevail Therapeutics Inc.PRVL · Jun 20, 2019 · $125M